



# NCCTG

NORTH CENTRAL CANCER TREATMENT GROUP

---

**Date:** October 16, 2009

**To:** NCCTG Primary Clinical Research Associates

**From:** Janis Wobschall  
Protocol Development Coordinator

**Re:** N027D, A Phase I Study of CCI-779 and Temozolomide in Combination with Radiation Therapy in Glioblastoma Multiforme

Please note that there were typographical errors on the attached status change notices for August 25, 2009 and October 7, 2009 and have been corrected as follows:

August 25, 2009:  
Effective date reflected August 25, ~~2008~~ **2009**  
(Mayo Clinic **Arizona, Florida**, Rochester only)

October 7, 2009:  
(Mayo Clinic **Arizona, Florida**, Rochester only)

These status change notices have been reposted with the respective effective dates remaining the same.

If you have any questions, please feel free to contact me.

Thank you.

North Central Cancer Treatment Group

N027D      A Phase I Study of CCI-779 and Temozolomide in Combination with Radiation  
Therapy in Glioblastoma Multiforme

Status Change Notice – August 25, 2009

**NOTICE OF STATUS CHANGE**

Patient accrual to Arm A (Mayo Clinic Arizona, Florida, Rochester only) has been met.  
Therefore Arm A of this study is temporarily closed effective Tuesday, August 25, 2009.

Patients currently on study should be followed according to the protocol.

**Please retain this notice with the protocol.**

North Central Cancer Treatment Group

N027D      A Phase I Study of CCI-779 and Temozolomide in Combination with Radiation  
Therapy in Glioblastoma Multiforme

Status Change Notice – October 7, 2009

**NOTICE OF STATUS CHANGE**

Arm B (Mayo Clinic Arizona, Florida, Rochester only) of this study is temporarily closed effective Wednesday, October 7, 2009 pending redesign of Arm B.

**Please retain this notice with the protocol.**